The firm’s first fund dedicated to biopharmaceuticals.
Jeito Capital is a leading global investment company. Jeito was founded and directed by Dr. Rafaèle Tordjman, a hematologist and former fellow in Paris University Hospitals and research scientist at INSERM, who has been an investor in life sciences for more than 20 years.
Jeito I has raised 534 million euros (630 million dollars) in September 2021
Jeito Capital has developed an approach focused on patient benefits, financing and accelerating cutting-edge medical innovation. Jeito supports and accompanies entrepreneurs through its multidisciplinary team of experts across the entire drug value chain, as well as through a significant capital contribution to ensure the growth of companies. Jeito thus contributes to the emergence of leaders in specific therapeutic areas and accelerates the commercialization of innovative treatments throughout the world, particularly in Europe and the United States, for the benefit of patients.
Jeito Capital has built a solid and diverse portfolio of European Biopharma companies. Jeito has invested in diversified therapeutic areas such as immuno-oncology, ophthalmology, rare skeletal diseases, severe respiratory diseases, fibrosis and associated cancers.
Further with the entrepreneur